Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sundeep Pharma Promoters Regain 100% Ownership from JRS Pharma | Contract Pharma
Breaking News

Sundeep Pharma Promoters Regain 100% Ownership from JRS Pharma

The company is poised to accelerate its R&D initiatives, expand its product portfolio, and pursue new opportunities.

Sudeep Pharma Private Limited’s promoters have completed the acquisition of shares from their joint venture partners, JRS PHARMA, regaining 100% ownership of the company—representing a significant step in Sudeep Pharma’s ongoing growth and development, enabling the company to pursue its vision.

Promoters of Sudeep Pharma, Sujit Bhayani & Family, entered into a joint venture in 2015 with JRS Pharma. Combining JRS Pharma’s expertise in excipients with Sudeep Pharma’s technological advancements and robust manufacturing capabilities resulted in significant growth and valuable cooperation over the past nine years.

Sudeep Pharma remains dedicated to delivering cutting-edge pharmaceutical solutions, maintaining the highest standards of quality, and ensuring continued customer satisfaction. The company is poised to accelerate its research and development initiatives, expand its product portfolio, and pursue new opportunities.

Both Sudeep Pharma and JRS Pharma assure all stakeholders that this transaction will have no impact on current operations or product availability. Customers can expect to receive the same levels of service and product quality that both companies have consistently provided.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters